Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.
PR Newswire - November 28, 1995
"The ability to produce nystatin in a liposomal formulation suitable for parenteral administration is critical to the development of Nystatin(LF) for systemic fungal infections. The liposomal formulation reduces the drug's toxicity while retaining its anti-fungal activity," said James M. Chubb, Ph.D., President of Aronex. "In addition to the patent in Europe, this technology is covered by an issued U.S. patent and is pending in Japan."
The patent (number 0567582b1), specifically covers the simple method of preparing a lyophilized preliposomal powder, which can be used to quickly and conveniently generate a liposomal formulation of nystatin upon reconstitution with saline. The patent is licensed to Aronex under a worldwide exclusive agreement from the University of Texas' M.D. Anderson Cancer Center in Houston.
Nystatin(LF) is currently in Phase II/III trials for the treatment of systemic fungal infections, a major problem for patients with impaired immune defense mechanisms, resulting from such diseases as HIV or cancer.
Aronex Pharmaceuticals, Inc. is developing and commercializing innovative pharmaceuticals for treating cancer and infectious diseases. Aronex has several products in clinical development including Nystatin(LF) for the treatment of systemic fungal infections; Annamycin(LF) for the treatment of solid tumors; and AR177 for HIV infection. The Company has a collaboration with Genzyme Corporation to develop Tretinoin(LF) for the treatment of Kaposi's sarcoma and acute promyelocytic leukemia.
CONTACT: James M. Chubb, Ph.D., President of Aronex Pharmaceuticals, Inc., 713-367-1666, or Michelle Linn, Sr. Account Executive of Feinstein Partners Inc., 617-577-8110/ 12:53 EST
Copyright (c) 1995/PR NewsWire. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, PR Newswire, 810 Seventh Avenue, New York, NY 10019.
951128
PR951148
Copyright © 1995 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.
Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .